Massard C - Search Results

1

Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Martin-Romano P, Ammari S, El-Dakdoukti Y, Baldini C, Varga A, Vuagnat P, Angevin E, Bahleda R, Gazzah A, Champiat S, Michot JM, Postel-Vinay S, Marabelle A, Soria JC, Boige V, Malka D, Ducreux M, Massard C, Hollebecque A. Martin-Romano P, et al. Among authors: massard c. Eur J Cancer. 2020 Sep;137:117-126. doi: 10.1016/j.ejca.2020.06.030. Epub 2020 Aug 2. Eur J Cancer. 2020. PMID: 32755794

2

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Among authors: massard c. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

3

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.

Gombos A, Izzedine H, Besse B, Massard C, Brocheriou I, Bahleda R, Soria JC. Gombos A, et al. Among authors: massard c. Invest New Drugs. 2010 Feb;28(1):102-5. doi: 10.1007/s10637-009-9247-3. Epub 2009 Apr 3. Invest New Drugs. 2010. PMID: 19343274

4

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Bahleda R, Massard C, Soria JC, Izzedine H, Cohen A, Ederhy S. Bahleda R, et al. Among authors: massard c. Invest New Drugs. 2010 Jun;28(3):350-2. doi: 10.1007/s10637-009-9252-6. Epub 2009 Apr 25. Invest New Drugs. 2010. PMID: 19396400

5

Electrolyte disorders related to EGFR-targeting drugs.

Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, Soria JC. Izzedine H, et al. Among authors: massard c. Crit Rev Oncol Hematol. 2010 Mar;73(3):213-9. doi: 10.1016/j.critrevonc.2009.03.012. Epub 2009 Apr 28. Crit Rev Oncol Hematol. 2010. PMID: 19403315 Review.

6

New agents in metastatic prostate cancer.

Fizazi K, Massard C. Fizazi K, et al. Among authors: massard c. Eur J Cancer. 2009 Sep;45 Suppl 1:379-80. doi: 10.1016/S0959-8049(09)70056-5. Eur J Cancer. 2009. PMID: 19775638 No abstract available.

7

Antiangiogenic agents and late anastomotic complications.

Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D. Deshaies I, et al. Among authors: massard c. J Surg Oncol. 2010 Feb 1;101(2):180-3. doi: 10.1002/jso.21447. J Surg Oncol. 2010. PMID: 19953576

8

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.

Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. Izzedine H, et al. Among authors: massard c. Eur J Cancer. 2010 Jan;46(2):439-48. doi: 10.1016/j.ejca.2009.11.001. Epub 2009 Dec 16. Eur J Cancer. 2010. PMID: 20006922 Review.

9

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K. Loriot Y, et al. Among authors: massard c. Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17. Eur J Cancer. 2010. PMID: 20483588

10

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC. Ferté C, et al. Among authors: massard c. Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12. Eur J Cancer. 2011. PMID: 21489779 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

475 results

Search Page

Filters